Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer

Area of Science:

• Oncology
• Immunology

Background:

• Metastatic renal cell carcinoma (mRCC) management has advanced with immune checkpoint inhibitors (ICIs).
• ICIs, including anti-PD-1/PD-L1 and anti-CTLA-4, are now standard frontline treatments, often combined with targeted therapies.
• These therapies offer improved outcomes compared to prior treatments.

Purpose of the Study:

• To discuss the identification, grading, and management of immune-related adverse events (irAEs) in mRCC patients treated with ICIs.
• To provide a case-based approach to understanding and managing ICI-related toxicities.

Main Methods:

• Case-based discussion format.
• Review of common and rare immune-related adverse events associated with ICIs in mRCC.
• Guidance on grading and clinical management strategies for irAEs.

Main Results:

• ICIs demonstrate significant clinical benefits in mRCC.
• Immune-related adverse events are a notable toxicity profile of ICIs.
• Common irAEs include colitis, hepatitis, dermatitis, and thyroiditis; rare but severe irAEs include myocarditis and pneumonitis.

Conclusions:

• Immune checkpoint inhibitors represent a significant therapeutic advance for metastatic renal cell carcinoma.
• Understanding and managing immune-related adverse events is crucial for optimizing ICI therapy.
• A systematic approach to irAEs ensures patient safety and treatment efficacy.